EDSA
Edesa Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$4.14
+0.00%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.03
From 52W high−77.34%
Volume41025.00
Market cap$39.91M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$4.03
From 52W high
−77.34%
Volume
41025.00
Market cap
$39.91M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.7x
P/E (TTM)
—
RSI (14)
34.6
MomentumView details →
1D Return
+0.00%
YTD Return
+185.21%
SummaryUpdated Jun 1, 2026
Edesa Biotech, Inc. (NASDAQ:EDSA) is a Canadian biopharmaceutical company founded in 2015 and headquartered in Markham, Ontario. The company went public in 2010 and focuses on acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases. As a clinical-stage biotechnology firm, Edesa operates without generating revenue from product sales, instead relying on funding to advance its drug candidates through various phases of clinical trials toward potential regulatory approval and commercialization.
Similar companies
Latest newsMore news →
Edesa Biotech announced the commencement of an underwritten public offering of its common shares (or pre-funded warrants in lieu thereof) and accompanying common share warrants, with a 30-day option for underwriters to purchase up to 15% additional shares and warrants.32d agoEdesa Biotech reported financial results for the three and nine months ended June 30, 2026.38d ago